Emerging Therapies in Chronic Spontaneous Urticaria

Allergy Asthma Immunol Res. 2019 Jul;11(4):470-481. English.

Taek Ki Min,1 and Sarbjit S. Saini2

1Pediatric Allergy and Respiratory Center, Department of Pediatrics, Soonchunhyang University Seoul Hospital, Seoul, Korea.

2Division of Allergy and Clinical Immunology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Abstract

Chronic spontaneous urticaria (CSU) is characterized by typically short-lived and fleeting wheals, angioedema or both, which occur spontaneously and persist for longer than 6 weeks. This term is applied to the most common subtype of chronic urticaria. The underlying pathophysiology for CSU involves mast cell and basophil degranulation with release of histamine, leukotrienes, prostaglandins and other inflammatory mediators. Although a variety of treatments exist, many patients do not tolerate or benefit from the existing therapies and even require more effective treatments. Omalizumab is currently the only licensed biologic for antihistamine-refractory CSU, and novel drugs are under development. This article reviews its current status regarding pathogenesis and approach to treatment as well as therapeutic agents that are under development for the treatment of CSU. PDF

The Role of Mobile Health Technologies in Allergy Care: an EAACI Position Paper

EAACI Position Paper 

 

Free Access

https://doi.org/10.1111/all.13953

Matricardi, P. M., Dramburg, S. , Alvarez‐Perea, A. , Antolín‐Amérigo, D. , Apfelbacher, C. , Atanaskovic‐Markovic, M. , Berger, U. , Blaiss, M. S., Blank, S. , Boni, E. , Bonini, M. , Bousquet, J. , Brockow, K. , Buters, J. , Cardona, V. , Caubet, J. , Cavkaytar, Ö. , Elliott, T. , Esteban‐Gorgojo, I. , Fonseca, J. A., Gardner, J. , Gevaert, P. , Ghiordanescu, I. , Hellings, P. , Hoffmann‐Sommergruber, K. , Kalpaklioglu, A. F., Marmouz, F. , Meijide Calderón, Á. , Mösges, R. , Nakonechna, A. , Ollert, M. , Oteros, J. , Pajno, G. , Panaitescu, C. , Perez‐Formigo, D. , Pfaar, O. , Pitsios, C. , Rudenko, M. , Ryan, D. , Sánchez‐García, S. , Shih, J. , Tripodi, S. , Van der Poel, L. , van Os‐Medendorp, H. , Varricchi, G. , Wittmann, J. , Worm, M. and Agache, I. (2019), The Role of Mobile Health Technologies in Allergy Care: an EAACI Position Paper. Allergy. Accepted Author Manuscript. doi:10.1111/all.13953

Abstract:

Mobile Health (mHealth) uses mobile communication devices such as smartphones and tablet computers to support and improve health‐related services, data flow and information, patient self‐management, surveillance, and disease management from the moment of first diagnosis to an optimized treatment. The European Academy of Allergy and Clinical Immunology created a task force to assess the state of the art and future potential of mHealth in allergology. The task force endorsed the “Be He@lthy, Be Mobile” WHO initiative and debated the quality, usability, efficiency, advantages, limitations, and risks of mobile solutions for allergic diseases.

Antibiotic overuse and allergy-related diseases: an epidemiological cross-sectional study in the grasslands of Northern China

 Therapeutics and Clinical Risk Management » Volume 15

Yan Lei Chen,¹ Weirong Joshua Sng,² De Yun Wang,² Xue Yan Wang¹

¹Department of Allergy, Beijing Shijitan Hospital, Capital Medical University, Beijing, People’s Republic of China; ²Department of Otolaryngology, National University Health System, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
DOI https://doi.org/10.2147/TCRM.S203719
Background: Several studies have shown that the use of antibiotics early in life significantly increases the risk of asthma in children. It is unclear whether antibiotics are more commonly used in patients with allergy-related diseases.

Sesame oleosins are minor allergens

• Letter to the Editor
• Open Access

• Anna M. EhlersEmail authorView ORCID ID profile,
• Madlen Rossnagel,
• Bettina Brix,
• Mark A. Blankestijn,
• Thuy-My Le,
• Waltraud Suer,
• Henny G. Otten and
• André C. Knulst

Western blot analysis of native sesame OAPs fraction to confirm the absence of seed storage protein traces (a) and the specific IgE (b) and IgG sensitisation pattern (c) of all included patients. a Western-Blot analysis of an intermediate purification step (before HIC) and of the final OAPs fraction (after HIC) with sera containing sIgE to sesame seed storage proteins and oleosins. Samples were separated by SDS-PAGE using a 4–12% Bis–Tris gel and blotted onto a nitrocellulose membrane. Bound IgE were detected by anti-human IgE antibodies conjugate labelled with alkaline phosphatase; PC is a oleosin-positive serum, SP is a sesame seed storage positive serum not used in this study, sera G1b_1, 4, 14, 11, 15–18, G2_12 and 10 are sera with specific IgE to sesame seed storage proteins and partly with slightly elevated sIgE levels to sesame oleosins. b IgE sensitisation pattern to sesame extract from ImmunoCAP and EUROLINE, sesame components and oleosins from sesame, walnut, soy, hazelnut and peanut expressed as EAST (Enzyme-Allergo-Sorbent Test classification)-classes and sorted by severity of symptoms to sesame, light grey: not determined. c IgG-sensitisation pattern to sesame components and oleosins from sesame, walnut, pecan and soy expressed as EUROLINE (EL)-intensities and sorted by severity of symptoms to sesame. G1a sesame allergic patients without detectable sIgE sensitisation, G1b sesame allergic patients with sIgE sensitisation, G2 sesame tolerant patients with sIgE sensitisation, PC positive control selected by sIgE to sesame oleosins, C1-3 positive controls selected by sIgE to peanut oleosins

Clinical and Translational Allergy20199:32

Abstract

Background

In daily practice, one-third of sesame allergic patients, confirmed by clinical history or food challenge, do not show any detectable specific IgE using current diagnostics. Currently used sesame extracts are water-based and therefore lacking hydrophobic proteins like oleosins.

Management of suspected immediate perioperative allergic reactions: an international overview and consensus recommendations

July 2019Volume 123, Issue 1, Pages e50–e64

Lene H. Garvey1,2,∗,Correspondence information about the author Lene H. Garvey†,‡,Email the author Lene H. Garvey

, 

Pascale Dewachter3,4,†,‡

, 

David L. Hepner5,†,‡

, 

Paul Michel Mertes6,†,‡

, 

Susanna Voltolini7,†,‡

, 

Russell Clarke8,9,‡

, 

Peter Cooke10,‡

, 

Tomaz Garcez11,‡

, 

Anne Berit Guttormsen12,‡

, 

Didier G. Ebo13,‡

, 

Philip M. Hopkins14,‡

, 

David A. Khan15,‡

, 

Peter Kopac16,‡

, 

Mogens Krøigaard1,‡

, 

Jose Julio Laguna17,‡

, 

Stuart Marshall18,19,‡

, 

Peter Platt8,9,‡

, 

Michael Rose20,‡

, 

Vito Sabato13,‡

, 

Paul Sadleir8,9,21,‡

, 

Louise Savic22,‡

, 

Sinisa Savic23,‡

, 

Kathrin Scherer24,‡

, 

Tomonori Takazawa25,‡

, 

Gerald W. Volcheck26,‡

, 

Helen Kolawole18,19,†,‡

PlumX Metrics

DOI: https://doi.org/10.1016/j.bja.2019.04.044

Article Info

• Abstract

• Full Text
• Images
• References
• Supplemental Materials

Summary

Suspected perioperative allergic reactions are rare but can be life-threatening. The diagnosis is difficult to make in the perioperative setting, but prompt recognition and correct treatment is necessary to ensure a good outcome. A group of 26 international experts in perioperative allergy (anaesthesiologists, allergists, and immunologists) contributed to a modified Delphi consensus process, which covered areas such as differential diagnosis, management during and after anaphylaxis, allergy investigations, and plans for a subsequent anaesthetic. They were asked to rank the appropriateness of statements related to the immediate management of suspected perioperative allergic reactions.

Emerging Therapies in Chronic Spontaneous Urticaria

Allergy Asthma Immunol Res. 2019 Jul;11(4):470-481. https://doi.org/10.4168/aair.2019.11.4.470

Taek Ki Min,1 and Sarbjit S. Saini2

1Pediatric Allergy and Respiratory Center, Department of Pediatrics, Soonchunhyang University Seoul Hospital, Seoul, Korea.

2Division of Allergy and Clinical Immunology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Abstract

Chronic spontaneous urticaria (CSU) is characterized by typically short-lived and fleeting wheals, angioedema or both, which occur spontaneously and persist for longer than 6 weeks. This term is applied to the most common subtype of chronic urticaria. The underlying pathophysiology for CSU involves mast cell and basophil degranulation with release of histamine, leukotrienes, prostaglandins and other inflammatory mediators. Although a variety of treatments exist, many patients do not tolerate or benefit from the existing therapies and even require more effective treatments. Omalizumab is currently the only licensed biologic for antihistamine-refractory CSU, and novel drugs are under development. This article reviews its current status regarding pathogenesis and approach to treatment as well as therapeutic agents that are under development for the treatment of CSU. PDF

Regulatory roles of IL-10–producing human follicular T cells

 View ORCID ProfilePablo F. Cañete, Rebecca A. Sweet, Paula Gonzalez-Figueroa, Ilenia Papa, Naganari Ohkura, Holly Bolton, Jonathan A. Roco, Marta Cuenca, Katharine J. Bassett, Ismail Sayin, Emma Barry, View Angel Lopez, David H. Canaday, Michael Meyer-Hermann, Claudio Doglioni, Barbara Fazekas de St Groth, Shimon Sakaguchi, Matthew C. Cook, Carola G. Vinuesa Correspondence email

DOI: 10.1084/jem.20190493 | Published June 17, 2019

Abstract

Mucosal lymphoid tissues such as human tonsil are colonized by bacteria and exposed to ingested and inhaled antigens, requiring tight regulation of immune responses. Antibody responses are regulated by follicular helper T (TFH) cells and FOXP3+ follicular regulatory T (TFR) cells. Here we describe a subset of human tonsillar follicular T cells identified by expression of TFH markers and CD25 that are the main source of follicular T (TF) cell–derived IL-10. Despite lack of FOXP3 expression, CD25+ TF cells resemble T reg cells in high CTLA4 expression, low IL-2 production, and their ability to repress T cell proliferation. CD25+ TF cell–derived IL-10 dampens induction of B cell class-switching to IgE. In children, circulating total IgE titers were inversely correlated with the frequencies of tonsil CD25+ TF cells and IL-10–producing TF cells but not with total T reg cells, TFR, or IL-10–producing T cells. Thus, CD25+ TF cells emerge as a subset with unique T and B cell regulatory activities that may help prevent atopy.

Download PDF

Characteristics of patients admitted to emergency department for asthma attack: a real-LIFE study

• Research article
• Open Access
• Open Peer Review
• BMC Pulmonary Medicine

• Laura Losappio,
• Enrico Heffler,
• Rossella Carpentiere,
• Monica Fornero,
• Cosimo Damiano Cannito,
• Francesco Guerrera,
• Francesca Puggioni,
• Riccardo Monti,
• Stefania Nicola,
• Giovanni Rolla and
• Luisa BrussinoEmail authorView ORCID ID profile

BMC Pulmonary Medicine201919:107

Abstract

Background

Asthma is a chronic disease affecting 30 million people in Europe under 45y. Poor control of Asthma is the main cause of emergency-department (ED) access, becoming the strongest determinant of the economic burden of asthma management.